Document:

Exhibit
10.4 

 

SEPARATION
AND RELEASE OF CLAIMS AGREEMENT

 

This
Separation and Release of Claims Agreement (“Agreement”) is entered into by and between Point of Care Nanotechnologies,
Inc., a Nevada corporation (the “Company”), on behalf of itself, subsidiaries, and other corporate affiliates
and each of their respective present and former directors, officers, directors, owners, shareholders, and agents, individually
and in their official capacities (collectively referred to as the “Company Group”), and Aymen El Salhy (the
“Director”), residing in STATE (the Company and the Director are collectively referred to as the “Parties”
and each as a “Party”) as of April 15, 2021 (the “Execution Date”).

 

WHEREAS,
the Director has resigned from the Company’s Board of Directors and all other positions, effective as of April 15, 2021.
(the “Separation Date”).

 

WHEREAS,
after the Separation Date, the Director will not represent himself as being a director, employee, officer, attorney, agent, or
representative of the Company Group for any purpose.

 

WHEREAS,
except as otherwise set forth in this Agreement, the Separation Date was the termination date for the Director for all purposes,
meaning the Director is not entitled to any further compensation, monies, or other benefits from the Company Group, including
coverage under any benefit plans or programs sponsored by the Company Group, as of the Separation Date.

 

NOW,
THEREFORE, in consideration of the following, the Parties hereby agree to the following.

 

1.            Return of Property.
The Director warrants and represents that he will return all Company Group property in the Director’s possession.

 

2.            Director Representations.
The Director specifically represents, warrants, and confirms that the Director:

 

(a)          has not filed any claims, complaints, or actions of any kind against the Company Group with any court of law, or local, state,
or federal government or agency;

 

(b)          has not engaged in and is not aware of any unlawful conduct relating to the business of the Company Group.

     

     

    

3.            Release.

 

(a)          Director’s General Release and Waiver of Claims

 

In
exchange for the consideration provided in this Agreement, the Director and the Director’s heirs, executors, representatives,
administrators, agents, and assigns (collectively, the “Releasors”) irrevocably and unconditionally fully and
forever waive, release, and discharge the Company Group, including each member of the Company Group’s parents, subsidiaries,
affiliates, predecessors, successors, and assigns, and all of their respective officers, directors, directors and shareholders,
in their corporate and individual capacities (collectively, the “Released Parties”), from any and all claims,
demands, actions, causes of actions, judgments, rights, fees, damages, debts, obligations, liabilities, and expenses (inclusive
of attorneys’ fees) of any kind whatsoever, whether known or unknown (collectively, “Claims”), that Director
may have or has ever had against the Released Parties, or any of them, by reason of any actual or alleged act, omission, transaction,
practice, conduct, occurrence, or other matter from the beginning of time up to and including the date of the Director’s
execution of this Agreement, including, but not limited to:

 

(i)           any and all claims under federal, state, local, or foreign law (statutory, regulatory, or otherwise) that may be legally waived
and released;

 

(ii)          any and all claims for compensation of any type whatsoever that may be legally waived and released;

 

(iii)         any and all claims arising under tort, contract, and quasi-contract law; and

 

(iv)         any and all claims for monetary or equitable relief.

 

However,
this general release and waiver of claims excludes, and the Director does not waive, release, or discharge: (A) claims that cannot
be waived by law and (B) any rights the Director has under the Company’s Director and Officer Liability Insurance Policy(ies).

 

(b)           Company Group Release of Director

 

In
exchange for the Releasors’ waiver and release of claims against the Released Parties, and non-revocation of any portion
of that release, the Company Group irrevocably and unconditionally fully and forever waive, release, and discharge the Director,
from any and all Claims that Company Group may have or has ever had against the Director, by reason of any actual or alleged act,
omission, transaction, practice, conduct, occurrence, or other matter from the beginning of time up to and including the date
of the Director’s execution of this Agreement, with the exception of claims arising out of or attributable to: (i) events,
acts, or omissions taking place after the Parties’ execution of the Agreement; (ii) the Director’s breach of any terms
and conditions of the Agreement; and (iii) the Director’s criminal activities or intentional misconduct occurring during
the Director’s employment with the Company Group.

 

4.             Knowing and Voluntary Acknowledgment.
The Director specifically agrees and acknowledges that:

 

(a)          the Director has read this Agreement in its entirety and understands all of its terms;

 

(b)          by
this Agreement, the Director has been advised to consult with an attorney before executing this Agreement;

    2

     

    

(c)          the Director knowingly, freely, and voluntarily assents to all of this Agreement’s terms and conditions including, without
limitation, the waiver, release, and covenants contained in it;

 

(d)          the Director is signing this Agreement, including the waiver and release, in exchange for good and valuable consideration in addition
to anything of value to which the Director is otherwise entitled;

 

(e)          the Director is not waiving or releasing rights or claims that may arise after the Director signs this Agreement; and

 

(f)           the Director understands that the waiver and
release in this Agreement is being requested in connection with the Director’s separation from the Company Group.

 

5.             Cooperation.
The parties agree that certain matters in which the Director has been involved during the Director’s employment may need
the Director’s cooperation with the Company in the future. Accordingly, for a period of six months after the Separation
Date, to the extent reasonably requested by the Company, the Director shall cooperate with the Company in connection with matters
arising out of the Director’s service to the Company; provided that the Company shall make reasonable efforts to minimize
disruption of the Director’s other activities.

 

6.             Governing Law, Jurisdiction, and Venue.
This Agreement and all matters arising out of or relating to this Agreement, whether sounding contract, tort, or statute, for
all purposes shall be governed by and construed in accordance with the laws of Nevada (including its statutes of limitations)
without regard to any conflicts of laws principles that would require the laws of any other jurisdiction to apply.

 

7.             Entire Agreement.
Unless specifically provided herein, this Agreement contains all of the understandings and representations between Company Group
and Director relating to the subject matter hereof and supersedes all prior and contemporaneous understandings, discussions, agreements,
representations, and warranties, both written and oral, regarding such subject matter.

 

8.             Modification and Waiver.
No provision of this Agreement may be amended or modified unless the amendment or modification is agreed to in writing and signed
by the Director and by the Chief Executive Officer of the Company. No waiver by either Party of any breach by the other party
of any condition or provision of this Agreement to be performed by the other party shall be deemed a waiver of any similar or
dissimilar provision or condition at the same or any prior or subsequent time, nor shall the failure of or delay by any Party
in exercising any right, power, or privilege under this Agreement operate as a waiver thereof to preclude any other or further
exercise thereof or the exercise of any other such right, power, or privilege.

 

9.             Severability.
Should any provision of this Agreement be held by a court of competent jurisdiction to be enforceable only if modified, or if
any portion of this Agreement shall be held to be unenforceable and thus stricken, such holding shall not affect the validity
of the remainder of this Agreement, the balance of which shall continue to be binding on the Parties with any such modification
to become a part hereof and treated as though originally set forth in this Agreement.

    3

     

    

10.           Captions.
Captions and headings of the sections and paragraphs of this Agreement are intended solely for convenience and no provision of
this Agreement is to be construed by reference to the caption or heading of any section or paragraph.

 

11.           Counterparts.
The Parties may execute this Agreement in counterparts, each of which shall be deemed an original, and all of which taken together
shall constitute one and the same instrument. Delivery of an executed counterpart’s signature page of this Agreement by
facsimile, email in portable document format (.pdf), or by any other electronic means intended to preserve the original graphic
and pictorial appearance of a document has the same effect as delivery of an executed original of this Agreement.

 

12.           No Admission of Liability.
Nothing in this Agreement shall be construed as an admission by the Director or the Company Group of any wrongdoing, liability,
or noncompliance with any federal, state, city, or local rule, ordinance, statute, common law, or other legal obligation.

 

13.           Notices. All
notices under this Agreement must be given in writing by personal delivery/regular mail/receipted email at the addresses indicated
in this Agreement or any other address designated in writing by either Party.

 

14.           Acknowledgment of Full Understanding.
THE DIRECTOR ACKNOWLEDGES AND AGREES THAT THE DIRECTOR HAS FULLY READ, UNDERSTANDS, AND VOLUNTARILY ENTERS INTO THIS AGREEMENT.
THE DIRECTOR ACKNOWLEDGES AND AGREES THAT THE DIRECTOR HAS HAD AN OPPORTUNITY TO ASK QUESTIONS AND CONSULT WITH AN ATTORNEY OF
THE DIRECTOR’S CHOICE BEFORE SIGNING THIS AGREEMENT. THE DIRECTOR FURTHER ACKNOWLEDGES THAT THE DIRECTOR’S SIGNATURE
BELOW IS AN AGREEMENT TO RELEASE COMPANY GROUP FROM ANY AND ALL CLAIMS THAT CAN BE RELEASED AS A MATTER OF LAW

 

IN
WITNESS WHEREOF, the Parties have executed this Agreement as of the Execution Date above.

 

	 	POINT
    OF CARE NANOTECHNOLOGIES, INC. 
	 	 
	 	By:
/s/ Dr. Raouf Guirguis                

        Name:
Dr. Raouf Guirguis

        Title:
Chairman and CEO

	DIRECTOR

         
	 
	Signature:
/s/ Aymen El Salhy                 

        Print
Name: Aymen El Salhy
	 

4Exhibit
10.5 

 

ASSIGNMENT
AND ASSUMPTION AGREEMENT

 

This
Assignment and Assumption Agreement is made and entered into this _15th__ day of _April___, 2021 (the “Agreement”),
between Point of Care Nanotechnologies, Inc., a Nevada corporation (“PCNT”), and Dr. Raouf Guirguis (“Assignee”)
(collectively, the “Parties” and, individually, a “Party”).

 

WHEREAS,
the PCNT wishes to create a subsidiary corporation (the “Subsidiary”) and transfer the all of its assets and
liabilities (the “Assets and Liabilities”) to the Subsidiary.

 

WHEREAS,
Assignee wishes to exchange their existing 26,000,000 shares of common stock of PCNT (the”Assignee Shares”)
for the all of the shares of the Subsidiary.

 

WHEREAS,
as of the date of this Agreement, there are an aggregate of 46,981,059 shares of common stock, par value $0.001 per share (the
“PCNT Common Stock”), of PCNT issued and outstanding;

 

WHEREAS,
PCNT intends to perform a reverse stock split (the “Reverse Split”) of the issued and outstanding shares of
PCNT Common Stock, rounding up for fractional shares resulting from the Reverse Split;

 

WHEREAS,
following the Reverse Split, PCNT intends to acquire another company and issue an undetermined amount of post-Reverse Split shares
of PCNT Common Stock to a new investment group (“New Investors”); and

 

WHEREAS,
PCNT desires to assign all of its rights, title and interests in its Assets and Liabilities to the Subsidiary and Assignee desires
to acquire all of the shares of the Subsidiary pursuant to the terms and conditions of this Agreement.

 

NOW,
THEREFORE, in consideration of the mutual covenants, terms, and conditions set forth herein, and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

 

1.     
Assignment and Assumption. Concurrently
upon receipt of all the consideration set forth in Section 2 below, PCNT shall sell, assign, grant, convey and transfer
to Subsidiary all of PCNT’s right, title and interest in and to Assets and Liabilities and the Subsidiary and the Assignee shall
accept such assignment and assume all of PCNT’s duties and obligations in connection with the Assets and Liabilities.

 

2.     
Consideration. In consideration for all of the shares of the Subsidiary, the Subsidiary, Assignee shall turn in the Assignee
Shares for cancellation to PCNT par value $0.001 per share which represents the entirety of the authorized Common Stock of Assignee.

    1

     

    

3.     
Conditions to Closing. The obligations of each Party to consummate the
transactions contemplated by this Agreement shall be subject to the fulfillment, at or prior to the Closing, of each of the following
conditions:

 

		(a)	Creation
                                         of Subsidiry. PCNT shall create a subsidiary corporation (the “Subsidiary”)
                                         and transfer all of its Assets and Liabilities to the Subsidiary. Assignee shall acquire
                                         the shares of the Subsidiary in exchange for the Assignee Shares.

 

		(b)	Actions
                                         of the Board of Directors. The Board of Directors of the PCNT (the “Board”)
                                         shall have resolved

 

		(i)	that
                                         the Reverse Split is in the best interests of PCNT,

 

		(ii)	to
                                         appoint a new Board of Directors and Officer,

 

		(iii)	to
                                         accept the resignations of the existing Board and Officers of the PCNT,

 

		(iv)	to
                                         approve a series A preferred shares issuance to the new Officer resulting in that Officer
                                         having 80% voting control of the PCNT.

 

		(v)	to
                                         accept this Agreement and authorize the new Board to execute the terms herein.

 

4.     
Representations and Warranties of PCNT. PCNT represents and warrants
to the Assignee that:

 

		(a)	It
                                         has the full right, power, and authority to enter into this Agreement and to perform
                                         the obligations hereunder;

 

		(b)	the
                                         execution of this Agreement, when executed and delivered by PCNT, shall constitute the
                                         legal, valid, and binding obligation of PCNT, enforceable against PCNT in accordance
                                         with its terms.

 

		(c)	the
                                         PCNT is exchanging the shares of the Subsidiary for the Assignee Shares solely for its
                                         own account for investment purposes and not with a view to, or for offer or sale in connection
                                         with, any distribution thereof except as identified in Section 3 above. PCNT acknowledges
                                         that the Shares are not registered under the Securities Act of 1933, as amended (the
                                         “Securities Act”), or any state securities laws, and that the Assignee
                                         Shares may not be transferred or sold except pursuant to the registration provisions
                                         of the Securities Act or pursuant to an applicable exemption therefrom and subject to
                                         state securities laws and regulations, as applicable;

 

		(d)	no
                                         broker, finder or investment banker is entitled to any brokerage, finder’s or other fee
                                         or commission in connection with the transactions contemplated by this Agreement;

 

		(e)	the
                                         Assets and Liabilities identified on Exhibit A are all the assets, receivables,
                                         liabilities and/or payables in which PCNT has rights, title, and/or interest and/ or
                                         obligations of PCNT;

    2

     

    

		(f)	it
                                         has sole and exclusive control (by ownership, license or otherwise) of the entire right,
                                         title, and interest identified in and to the Assets and Liabilities identified on Exhibit
                                         A;

 

		(g)	covenants
                                         that it shall operate its remaining business, together with all related assets, until
                                         the Closing and shall transfer all right, title and interest in the name “Point
                                         of Care Nanotechnology, Inc.” to the Subsidiary as soon as the PCNT name change
                                         is approved;

 

		(h)	neither
                                         its grant of the assignment nor its performance of any of its obligations, under this
                                         Agreement does or to its knowledge will at any time during the Term:

 

		(i)	conflict
with or violate any applicable U.S. law, rule or regulation;

 

		(ii)	require
the consent, approval, or authorization of any governmental or regulatory authority or other third party; or

 

		(iii)	require
the provision of any payment or other consideration to any third party.

 

		(i)	it
                                         has not granted and will not grant any licenses or other contingent or non-contingent
                                         right, title, or interest under or relating to Assets and Liabilities, and is not or
                                         will not be under any obligation, that does or will conflict with or otherwise affect
                                         this Agreement, including any of PCNT’s representations, warranties, or obligations,
                                         or Assignee’s rights or licenses hereunder;

 

		(i)	to
its knowledge, no prior art or other information exists that would adversely affect the validity, enforceability, term, or scope
of this Agreement;

 

5.     
Representations and Warranties of Assignee. Assignee represents, warrants and covenants as follows:

 

		(a)	it
                                         is duly organized, validly existing, and in good standing as a corporation or other entity
                                         as represented herein under the laws and regulations of its jurisdiction of incorporation,
                                         organization, or chartering;

 

		(b)	it
                                         has the full right, power, and authority to enter into this Agreement and to perform
                                         its obligations hereunder;

 

		(c)	the
                                         execution of this Agreement by its representative whose signature is set forth at the
                                         end hereof has been duly authorized by all necessary corporate action of the party;

    3

     

    

		(d)	when
                                         executed and delivered by such party, this Agreement shall constitute the legal, valid,
                                         and binding obligation of that party, enforceable against that party in accordance with
                                         its terms;

 

		(e)	the
                                         Assignee Shares have been duly authorized for issuance pursuant to this Agreement and
                                         when issued shall be free and clear of all liens, encumbrances, security agreements,
                                         equities, options, claims, charges, and restrictions other than imposed by law and shall
                                         be deemed to fully paid and non-assessable shares of Common Stock of Assignee;

 

		(f)	to
                                         the best of Assignee’s knowledge, there are no suits, actions, arbitrations, or
                                         legal, administrative, or other proceedings, or governmental investigations pending,
                                         or threatened, against or affecting it or its business, assets, financial condition,
                                         the Assignee Shares, its officers or directors;

 

		(g)	the
                                         consummation of the transactions contemplated by this Agreement will not result in or
                                         constitute a default or an event that, with notice or lapse of time or both, would be
                                         a default, breach or violation of any lease agreement, promissory note, commitment, indenture,
                                         mortgage, deed of trust, or other agreement, instrument, or arrangement to which Assignee
                                         is a party, or by which Assignee is bound;

 

		(h)	There
                                         does not exist an entity or individual that has any rights of first refusal to purchase
                                         any of the Assignee Shares; and

 

		(i)	no
                                         broker, finder or investment banker is entitled to any brokerage, finder’s or other fee
                                         or commission in connection with the transactions contemplated by this Agreement.

 

6.     
Closing. The following matters shall apply to the Closing of the transaction contemplated herein:

 

		(a)	Time
                                         and Place. The transfer of the Assignee Shares by Assignee to PCNT and PCNT’s
                                         assignment of the Subsidiary shares to Assignee (the “Closing”) shall
                                         take place at PCNT’s principal office after the complete satisfaction of the conditions
                                         herein unless waived by the parties, at a time and place as the Parties may mutually
                                         upon (the “Closing Date”).

 

		(b)	Assignee’s
                                         Obligations. At the Closing, Assignee shall deliver to PCNT all originl certificates
                                         representing the Assignee Shares to be transferred hereunder (whereupon the stock ledger
                                         and other internal records of the corporation shall be changed to reflect the transfer
                                         of the Assignee Shares to PCNT).

    4

     

    

		(c)	PCNT’s
                                         Obligations. At the Closing, PCNT shall transfer all the shares of the Subsidiary
                                         to Assignee, and shall deliver all documents necessary to effectuate such transfer.

 

7.     
Nature and Survival of Representations and Obligations. The representations and warranties made by the Parties and their respective
obligations to be performed pursuant to the terms hereof, shall survive the Closing indefinitely.

 

8.     
Termination. This Agreement may be terminated at any time prior to the Closing:

 

		(a)	by
                                         the mutual written consent of PCNT and Assignee;

 

		(b)	by
                                         mutual consent if the transactions contemplated by this Agreement are not consummated
                                         by October 1, 2021 (the “Drop Dead Date”);

 

		(c)	by
                                         Assignee by written notice to PCNT if:

 

		(i)	Assignee
                                         is not then in material breach of any provision of this Agreement and there has been
                                         a material breach, inaccuracy in or failure to perform any representation, warranty,
                                         covenant or agreement made by PCNT pursuant to this Agreement and such breach, inaccuracy
                                         or failure cannot be cured by PCNT by the Drop Dead Date; or

 

		(ii)	any
                                         of the conditions set forth in Section 3 shall not have been fulfilled by
                                         the Drop Dead Date, unless such failure shall be due to the failure of Assignee to perform
                                         or comply with any of the covenants, agreements or conditions hereof to be performed
                                         or complied with by it prior to the Closing;

 

		(d)	by
                                         PCNT by written notice to Assignee if:

 

		(i)	PCNT
                                         is not then in material breach of any provision of this Agreement and there has been
                                         a material breach, inaccuracy in or failure to perform any representation, warranty,
                                         covenant or agreement made by Assignee pursuant to this Agreement and such breach,
                                         inaccuracy or failure cannot be cured by Assignee by the Drop Dead Date; or

 

		(ii)	any
                                         of the conditions set forth in Section 3 shall not have been fulfilled
                                         by the Drop Dead Date, unless such failure shall be due to the failure of PCNT to perform
                                         or comply with any of the covenants, agreements or conditions hereof to be performed
                                         or complied with by it prior to the Closing; or

    5

     

    

		(e)	by
                                         Assignee or PCNT in the event that:

 

		(i)	there
                                         shall be any law that makes consummation of the transactions contemplated by this Agreement
                                         illegal or otherwise prohibited; or

 

		(ii)	any
                                         Governmental Authority shall have issued a Governmental Order restraining or enjoining
                                         the transactions contemplated by this Agreement, and such Governmental Order shall have
                                         become final and non-appealable.

 

9.     
Effect of Termination. In the event of the termination of this Agreement in accordance with Section
8, this Agreement shall forthwith become void and there shall be no liability on the part of any party hereto except:

 

		(a)	as
                                         set forth in Section 9; and

 

		(b)	that
                                         nothing herein shall relieve any party hereto from liability for any intentional breach
                                         of any provision hereof.

 

10. 
Expenses. Except as otherwise expressly provided herein, all costs and expenses, including, without limitation, fees
and disbursements of counsel, financial advisors and accountants, incurred in connection with this Agreement and the transactions
contemplated hereby shall be paid by the party incurring such costs and expenses, whether or not the Closing shall have occurred.

 

11. 
General Provisions

 

		(a)	Entire
                                         Agreement. This Agreement and all Exhibits hereto contain the entire understanding
                                         and agreement of the Parties with respect to matters addressed herein, and supersedes
                                         any prior understandings and agreements among them respecting the subject matter of this
                                         Agreement. No modification of this Agreement shall be valid unless it is in writing and
                                         signed by each of the Parties.

 

		(b)	Further
                                         Assurances.
                                         Each of the Parties hereto shall execute and deliver, at the reasonable request of the
                                         other Party hereto, such additional documents, instruments, conveyances and assurances
                                         and take such further actions as such other party may reasonably request to carry out
                                         the provisions hereof and give effect to the transactions contemplated by this Agreement.

 

		(c)	Severability.
                                         If one or more of the provisions contained in this Agreement shall for any reason
                                         be held to be unenforceable or excessively broad as to time, duration, scope, activity
                                         or subject, such provision will be construed, by limiting or reducing it, so as to be
                                         enforceable to the extent compatible with the then-applicable law. In the event of any
                                         question as to the interpretation of any provision herein, such question shall not be
                                         resolved by resort to any rule or maxim which resolves it against the drafting party.
                                         In the event any one or more provisions contained in this Agreement are held by a court
                                         or other tribunal to be invalid or unenforceable, the remaining provisions shall continue
                                         in full force and effect without being impaired or invalidated in any way.

    6

     

    

		(d)	Governing
                                         Law; Jurisdiction. This Agreement and the rights and obligations of the Parties herein,
                                         shall be construed in accordance with the laws of the State of New York and applicable
                                         federal law. The Parties hereby consent to the jurisdiction and venue of the state or
                                         federal courts located in the State of New York, County of New York. The substantially
                                         prevailing party in any adjudication, arbitration or related settlement shall be entitled
                                         to recover such party’s reasonable attorneys’ fees, including costs and expenses
                                         of collection, enforcement, and appeal, in addition to all other recovery and relief.

 

		(e)	Assignment.
                                         Neither party may assign its rights and obligations under this Agreement except with
                                         the prior written consent of the other. Any attempt to assign or delegate prior to the
                                         Closing without such consent shall be ineffective. After the Closing, Assignee may assign
                                         its rights under this Agreement without the prior written consent of the PCNT.

 

		(f)	Arbitration.
                                         The Parties agree to first try to resolve any dispute or controversy arising out
                                         of, in connection with, or relating to this Agreement between them. If they are unable
                                         to do so, the Parties then agree to seek mediation before a mediator acceptable to each
                                         of the Parties. If mediation fails to resolve the dispute or controversy, the Parties
                                         agree to submit the dispute or controversy to binding arbitration conducted by a three-person
                                         arbitrator panel mutually selected by the Parties, or, in the event the Parties cannot
                                         agree upon such an arbitrator, then by the American Arbitration Association, in New York,
                                         New York. The arbitration shall be conducted pursuant to the American Arbitration Association’s
                                         then-existing rules and regulations. Any decision so rendered in arbitration shall be
                                         binding and final on all Parties.

 

		(g)	Counterparts.
                                         This Agreement may be executed in several counterparts and all so executed, shall
                                         constitute one Agreement, binding on the Parties hereto even though, all the Parties
                                         are not signatories to the original or the same counterpart.

 

		(h)	Facsimile
                                         Transmission. Facsimile transmission of any signed original document, and retransmission
                                         of any signed facsimile transmission, shall be the same as transmission of an original.
                                         Parties will confirm signatures transmitted by facsimile by signing an original document.

 

		(i)	Binding
                                         Effect. This Agreement shall be binding upon and inure to the benefit of the Parties,
                                         and their respective successors and assigns, subject to the assignment provisions set
                                         forth above.

    7

     

    

		(j)	Further
                                         Documentation. The Parties recognize that Assignee is a publicly traded Assignee,
                                         and as such other documentation may be required to effectuate all the terms of this Agreement.
                                         Further, the Parties recognize that at Closing management of Assignee will concurrently
                                         change, requiring the filing of various documents with state and/or federal governments
                                         setting forth the change in management. The Parties agree to promptly execute any and
                                         all future documentation necessary to complete all of the promises and conveyances set
                                         forth in this Agreement. 

 

[SIGNATURE
PAGE FOLLOWS]

    8

     

    

IN
WITNESS WHEREOF, the Parties have duly executed this Agreement as of the date first written above.

	 	 	 	 
	PCNT	Point of Care Nanotechnology.
	 	 
	 	/s/ Aymen El Salhy
	 	Name: Aymen El Salhy
	 	Title: Director
	 	 	 	 
	Assignee	Dr. Raouf Guirguis
	 	 
	 	By: /s/ Dr. Raouf Guirguis
	 	Name: Dr. Raouf Guirguis

 

NOTARY

	STATE OF ___________	)
	 	)     ss:
	COUNTY OF __________	)

 

On
the _______day of ___________ in the year_____, before me, the undersigned notary public, personally appeared _________________________,
personally known to me or proved to me on the basis of satisfactory evidence to be the individual whose name is subscribed to
the within instrument and acknowledged to me that he executed the same in his capacity, and that by his signature on the instrument,
the individual, or the person upon behalf of which the individual acted, executed the instrument.

 

	 	WITNESS my hand and official seal.
	 	 	 
	 	Notary Signature
	 	 
	 	[NOTARY SEAL]

    9

     

    

EXHIBIT
A

[Point
of Care Nanotechnologies Assets and Liabilities]

 

100%
of all liabilities including Accounts Payable, Debt of any kind, Judgments against Point of Care Nanotechnologies (PCNT) of any
kind as of April 15, 2021

 

100%
of any and all legal actions taken against PCNT with claims prior to April 15, 2021

 

100%
of all Assets as of April 15, 2021 including the name “Point of Care Nanotechnologies”

    10

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00334-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00334-of-00352.parquet"}]]